{"doi":"10.1016/j.dscb.2023.100114","title":"The role of Memantine in slowing cognitive decline in patients with Down syndrome–A systematic review and meta analysis","abstract":null,"journal":"Brain Disorders","year":2024,"id":641866,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":404111,"name":"Shamas Ghazanfar","orcid":"0000-0002-3659-4491","position":1,"is_corresponding":false},{"id":1669144,"name":"Shazil Ahmed Gangat","orcid":null,"position":2,"is_corresponding":false},{"id":1669145,"name":"Wajeeha Bilal Marfani","orcid":null,"position":3,"is_corresponding":false},{"id":1669146,"name":"S.M.Ashraf Jahangeer Al'Saani","orcid":null,"position":4,"is_corresponding":false},{"id":1669147,"name":"Zainab Syyeda Rahmat","orcid":null,"position":5,"is_corresponding":false},{"id":1596610,"name":"Zarmina Islam","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The role of Memantine in slowing cognitive decline in patients with Down syndrome–A systematic review and meta analysis","abstract":"Memantine, an NMDA antagonist, has shown to be an effective and well-tolerated pharmacological therapy for the reduction of cognitive decline in the general population with Alzheimer's Disease. Individuals with Down syndrome (trisomy 21) have higher rates of cognitive decline than the general population in addition to a greatly increased risk for the development of early-onset Alzheimer's Disease. The potential efficacy of Memantine as a therapy for cognitive improvement in DS patients is not well understood. To assess the effectiveness of Memantine in comparison to placebo as a pharmacological therapy for patients with Down syndrome. Multiple databases including Pubmed, CENTRAL, CDSR, and clinicaltrials.gov were searched with terms including “Memantine Hydrochloride” and “Trisomy 21.” Randomized, double-blind, placebo-controlled trials measuring tolerability, efficacy, and safety of memantine in DS patients were used. Three (3) studies were ultimately included. Standard Mean Difference (SMD), Odds Ratio (OR) and 95% confidence intervals (CIs) were calculated to assess the significance of intervention. No statistically significant therapeutic effect was found upon administration of Memantine relative to placebo in DS patients.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":null,"openalex_id":"https://openalex.org/W4390166088","authors":[],"funders":[],"total_grants":0,"fwci":0.1512,"citation_percentile":0.37656904,"influential_citations":0,"citation_trend":[{"year":2025,"count":2}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.dscb.2023.100114","host_type":"journal"},{"url":"https://doi.org/10.1016/j.dscb.2023.100114","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2666459323000513?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2666459323000513?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doaj.org/article/9c47d00fe11847f7b6e455feaef0ac25","host_type":"repository"}],"fields_of_study":["Down syndrome and intellectual disability research","Alzheimer's disease research and treatments"],"mesh_terms":[],"keywords":["Memantine","Tolerability","Placebo","Medicine","Internal medicine","Population","Odds ratio","Randomized controlled trial","Cognitive decline","Psychology","Adverse effect","Dementia","Disease","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T20:44:10.571523Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}